|
Days in EB formation | Differentiation conditions | Selection | Functional assay | Markers studied | Cells line(s) | Reference |
|
None | Coculture of hESC with OP9 cells in serum-containing media | FACS purification with CD73+ | Differentiation in vitro to osteoblasts, chondrocyte, and adipocytes | Cell surface markers: CD29, CD44, CD54, CD73, CD90, CD105 D21: mineralization D17: lipid droplets | Human-H1 and H9 | [24] |
None | Monolayer direct differentiation in presence of bFGF2 and PDGF AB | FACS purification with CD105+ and CD24− | Differentiation in vitro to osteoblasts, chondrocyte and adipocytes | Cell surface markers: CD29, CD44, CD49a, CD105, CD166 D21: mineralization D14: lipid droplets D21: proteoglycans | Human-H1 and HUES9 | [25] |
None | Spontaneous monolayer differentiated cells from hESC colonies | Serum (10%) | Differentiation in vitro to osteoblasts and adipocytes | Cell surface markers: CD13, CD44, CD71, CD73, CD105, CD166 After 3 weeks: mineralizationa D21: lipid droplets | Human-H1 | [26] |
None | Coculture of hESC with OP9 cells in serum containing media | FACS purification with CD73+ | Differentiation in vitro to osteoblasts, chondrocyte, and myoblasts | Cell surface markers: CD29, CD44, CD54 CD73, CD90, CD105, CD106, CD166, STRO1 | Human-H1 and H9 | [27] |
|